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Background: Reports have shown that visceral adipose tissue (VAT) is more closely linked 
to cardiovascular risk factors (CRFs) than subcutaneous adipose tissue (SAT). We aimed to 
elucidate preferential abdominal fat loss and the correlations between abdominal fat reductions 
and changes in CRFs achieved with a moderate low-carbohydrate diet (LCD) in patients with 
type 2 diabetes (T2DM).
Patients and methods: Fifty-two outpatients (28 men and 24 women, mean age ± SD: 
60.0 ± 10.5 years) with hemoglobin A1c (HbAlc) levels $ 6.5% were on an LCD for 6 months. 
Over a 6-month period, we measured their abdominal fat distribution (using CT) and assessed 
CRFs, including body mass index (BMI), HbA1c, fasting blood glucose (FBG), serum insulin, 
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 
and triglyceride levels.
Results: The patients showed good compliance with the LCD (1812 ± 375 kcal/day, % carbo-
hydrate:fat:protein = 35:40:19 for men; 1706 ± 323 kcal/day, % carbohydrate:fat:protein = 
41:36:21 for women). Significant decreases (P = 0.05) in BMI and HbA1c levels were observed, 
along with an increase in HDL-C (P = 0.021) in men and a decrease in LDL-C (P = 0.001) 
in women. VAT (–21.6 cm², P , 0.001 in men; –19.6 cm², P , 0.001 in women) and SAT 
(–13.5 cm², P = 0.004 in men; –19.1 cm², P = 0.003 in women) significantly decreased. The loss 
of VAT (%∆VAT) was greater than that of SAT (%∆SAT) in women (P = 0.022). A similar 
but not significant predominance of VAT loss was detected in men (P = 0.111). In women, the 
%∆SAT significantly correlated with changes in FBG (∆FBG) (r = 0.417) and HDL-C (∆HDL) 
(r = –0.720), as was %∆VAT with changes in triglyceride (∆TG) (r = 0.591).
Conclusion: Six months of a moderate LCD resulted in preferential VAT loss only in women, 
with significant correlations between %∆SAT and both ∆HDL and ∆FBG, as well as between 
%∆VAT and ∆TG. Our results suggest that an LCD has the potential to reduce abdominal fat 
in patients with T2DM and deterioration of serum lipid profiles.
Keywords: low-carbohydrate diet, visceral adipose tissue, subcutaneous adipose tissue, 
  cardiovascular risk factors
Introduction
Low-carbohydrate diets (LCDs) have attracted interest for weight loss, glycemic con-
trol, and the management of cardiovascular risk factors in overweight patients with 
type 2 diabetes (T2DM).1,2 Among their reported advantages over high-carbohydrate 
diets (HCDs) are improvements in both serum high-density lipoprotein cholesterol 
(HDL-cholesterol) levels and triglyceride levels in obese patients.3–5
The proportion of energy obtained from carbohydrates in East Asian populations 
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compared with Western populations.6–9 Therefore, com-
pared with HCDs, moderate (non-ketogenic) LCDs, but 
not strict (ketogenic) LCDs, may be sufficiently effective 
for glycemic control in East Asian patients with T2DM. 
Moreover, a moderate LCD is more acceptable to patients 
with T2DM because they are not required to strictly limit 
carbohydrates.10,11 Indeed, we demonstrated the efficacy of 
a moderate LCD (30%–45% carbohydrate diet) in glycemic 
control, weight loss, and improvement of serum lipid profiles 
in T2DM patients with a low attrition rate.11,12 Even in the 
Western population, strict and moderate LCDs are reported 
to be equally effective in controlling body weight and serum 
lipid profiles.13
It has been proposed that abdominal fat accumulation 
raises cardiovascular risk. As compared with subcutane-
ous adipose tissue (SAT), visceral adipose tissue (VAT) 
in particular is more closely linked to glucose intolerance, 
hypertension, dyslipidemia, and insulin resistance.14–16 
Therefore, VAT is widely assumed to be a major predic-
tor of metabolic syndrome and insulin resistance. Indeed, 
experimental studies have demonstrated that VAT and 
SAT play different physiological and biochemical roles.16 
Men have significantly more VAT than women, which 
may explain why women have fewer cardiovascular 
events than men.17 Thus, if moderate LCDs result in a 
greater decrease in VAT than SAT, such LCDs may be 
useful for controlling not only blood glucose levels, but 
also abdominal fat.
Many intervention studies involving HCDs and either 
exercise or drugs have been conducted to assess changes 
in abdominal fat distribution in obese subjects. However, 
although HCDs can result in absolute VAT and SAT loss, 
these diets do not result in preferential abdominal fat loss.18 
To date, only a few studies have examined the effects of 
LCDs on preferential abdominal fat loss and the associa-
tions between the loss of adipose tissue and improvement in 
cardiovascular risk factors in nonobese and obese patients 
with and without T2DM.19
Therefore, in the present study, we investigated which 
abdominal fat tissues (VAT or SAT) would be preferentially 
reduced by a 6-month moderate LCD. The subjects were 
non-obese patients with T2DM who were typical of those 
commonly treated in Japan.20,21 We also sought to determine 
whether decreases in VAT or SAT were associated with 
changes in cardiovascular risk factors (body mass index 
[BMI], blood pressure [BP], hemoglobin A1c [HbAlc] levels, 
fasting blood glucose [FBG], serum insulin [IRI] and serum 
lipid profiles).
Patients and methods
We invited all new outpatients with T2DM and HbA1c levels 
of 6.5% or above to participate in a 6-month intervention 
study from April 2007 to November 2008 at the Haimoto 
Clinic. Patients with serum creatinine levels . 1.5 mg/dL, 
severe complications from diabetes (proliferative   retinopathy, 
symptomatic neuropathy, or a diabetic foot), ketoacidosis, 
soft drink ketosis, cancer, severe heart failure, and liver 
cirrhosis were excluded. Five patients on hormone and/or 
insulin treatment were also excluded due to the considerable 
effects of these drugs on body weight (BW) and serum insulin 
levels. The remaining 63 patients participated in the study.
We measured the participants’ BW, BP, and HbA1c levels 
every month. Levels of FBG and serum insulin, triglyceride 
(TG), low-density lipoprotein cholesterol (LDL-C) and 
HDL-C were analyzed in the fasting state at baseline and after 
6 months. Changes in VAT, SAT, total adipose tissue (TAT) 
and waist circumference (WC) were also assessed at baseline 
and after 6 months by computed tomography (CT).
All participants gave informed consent, and the study 
  protocol was approved by the Ethics Committee of the 
Nagoya Tokushukai General Hospital.
Laboratory methods
Plasma glucose concentrations were determined by enzy-
matic methods (Shino-Test Co. Kanagawa, Japan). Serum 
insulin levels were measured using the standard double 
antibody radioimmunoassay method (Fujirebio Inc. Tokyo, 
Japan). Enzymatic methods were used to measure TG levels 
(Daiichi Pure Chemicals Co., Tokyo, Japan). Direct methods 
were used to assay serum LDL-C and HDL-C levels   (Daiichi 
Pure Chemicals Co., Tokyo, Japan). HbA1c levels were 
measured using high-performance liquid chromatography 
(Arkley Co., Kyoto, Japan).
Assessment of body composition
BW was determined using an electronic scale while patients 
were wearing only underwear. BMI was calculated by divid-
ing weight in kilograms by the square of height in meters. To 
eliminate the effect of sex and age, we used the standard devia-
tion score of BMI as well as crude BMI   values. The score was 
computed using the following formula: (BMI – mean)/SD. 
We used the average and standard   deviation of BMI by sex 
and 10-year age group in the National Health and Nutrition 
Survey, Japan, 200922 because of the small number of partici-
pants in some age groups in the present study.
The surface areas of VAT and SAT were measured by CT 
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patients were scanned at the navel. These areas and WC were 
measured using image analysis software (Hitachi Medical Cor-
poration Fat Pointer, version 1.10) as described previously.23
The carbohydrate-reduced diet
The main principle of the LCD used in this study was 
to eliminate carbohydrate-rich foods depending on each 
patient’s HbA1c levels, as described previously.11,12 In brief, 
patients with HbA1c levels , 9.0% were asked to eliminate 
carohydrate-rich foods from their dinner, whereas patients 
with an HbA1c level $ 9.0% were asked to eliminate car-
bohydrates twice a day (from breakfast and dinner). It was 
easy for patients to stay on the LCD because no strict 
protein:fat:carbohydrate (PFC) ratio was prescribed, and they 
were permitted to eat as much protein and fat as they wanted, 
including saturated fat. There were no other restrictions.
A dietician (TS) gave instructions to all participants 
3 times during the first month and once a month thereafter. 
The participants were instructed to maintain their baseline 
physical activity level throughout the study period. Their 
dietary intake was assessed after 5 months from 3-day 
food records and an interview with a dietitian and the data 
were analyzed using the HealthyMaker432 (mushroomsoft, 
Okayama, Japan). The participants had not previously been 
instructed to follow a LCD before this intervention. They 
were asked about changes in their physical activity levels on 
a questionnaire that they filled out at the end of the study.
Statistical analysis
Data are presented as mean ± SD. Either the paired t-test or 
its nonparametric counterpart (Wilcoxon signed rank test) 
was used to assess changes in all the parameters during the 
6-month period. The unpaired t-test was applied to assess the 
differences in VAT and SAT at baseline and in the percentage 
of dietary macronutrient intake between men and women.
We compared the ratio of VAT area to SAT area (V/S 
ratio) at baseline and after the 6-month period. The changes in 
some variables during the 6-month study period (ie, 6-month 
value minus baseline value) are presented as   ∆variable 
(eg, ∆BMI, ∆SBP, ∆DBP, ∆FBG, ∆IRI, ∆HbA1c, ∆TG, 
∆LDL-C, and ∆HDL-C). We used %∆VAT,  %∆SAT and 
∆V/S as indicators of differential changes in VAT or SAT, 
although various parameters have been used in previous inter-
vention studies (eg, ∆VAT,  ∆SAT, ∆VAT/∆SAT, %∆VAT, 
%∆SAT, %∆VAT/%∆SAT, V/S, and ∆V/S).18,19,24–29 The 
parameters %∆VAT and %∆SAT were computed using the 
following formula: 100 – (100 × [FAT area at 6 months/FAT 
area at baseline]).
The correlations between abdominal fat distribution and 
either cardiovascular risk factors or body composition at 
baseline and the correlations between changes in these vari-
ables over the 6-month period were assessed with   Spearman 
correlation coefficients. Multiple regression analyses adjusted 
for age were performed on the significant and strong correla-
tions between changes in abdominal fat and cardiovascular 
risk factors. All statistical analyses were performed using the 
SPSS statistical package (version 11.0; SPSS, Inc., Chicago, 
IL). P values less than 0.05 were considered to be statisti-
cally significant.
Results
Baseline characteristics of patients 
Of the 63 patients enrolled in the study, 2 patients voluntarily 
dropped out, 2 refused the CT assessment at 6 months, 3 began 
to require insulin treatment, and 4 were hospitalized because 
of diseases other than T2DM. After excluding these patients, 
52 were left for the analyses (28 men, mean age ± SD: 
57.3 ± 10.6 years, range: 35–73 years and 24 women, mean 
age ± SD: 63.6 ± 9.5 years, range: 34–82 years). All but one 
of the female participants were postmenopausal.
The patients’ characteristics at baseline are shown in 
Table 1. The mean BMI was 25.4 ± 4.5 kg/m² for men and 
23.9 ± 3.4 kg/m² for women, and only 5 patients exceeded 
30.0 kg/m². The mean standard deviation score of BMI was 
0.49 ± 1.34 for men and 0.30 ± 0.93 for women.
HbA1c levels were 8.4% ± 1.5% in men and 8.6% ± 2.0% 
in women. VAT was much larger in men than in women 
(men: 150.9 ± 57.5 cm², women: 99.6 ± 51.7 cm²), whereas 
SAT was larger in women (men: 123.4 ± 70.7 cm², women: 
187.3 ± 70.0 cm²). No changes in physical activity levels 
during the study period were reported in the questionnaire.
As for the correlations of VAT or SAT distribution and 
WC with cardiovascular risk factors in men, we found a 
strong positive correlation between VAT and BMI (Spearman 
correlation coefficient [r] = 0.669, P , 0.001). There were 
also strong, positive correlations between SAT, TAT, or WC 
and either BMI (r = 0.590, 0.819 or 0.806, respectively and 
P # 0.001 for all) or serum insulin levels (r = 0.655, 0.565, 
0.673 and P , 0.001, P = 0.002, P , 0.001, respectively). 
Moderate inverse correlations between either SAT or WC 
and serum HDL-C levels (r = –0.473, –0.472 and P = 0.020 
or P = 0.020, respectively) were also observed. In women, 
we found strong positive correlations between VAT, SAT, 
TAT, or WC and either BMI (r = 0.652, 0.730, 0.796, or 0.865 
and P # 0.001 for all) or serum insulin levels (r = 0.658, 
0.663, 0.762, or 0.759 and P , 0.001 for all). A significant Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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inverse correlation between VAT and serum HDL-C levels 
(r = 0.567 and P = 0.011) was also observed. Applying the 
standard deviation score of BMI did not materially change 
the correlations of VAT, SAT, TAT, or WC with BMI in 
both sexes (P # 0.001 for all).
Assessment of dietary intake
Total energy intake, assessed by 3-day food records, was 
1812 ± 375 kcal/day for men and 1706 ± 323 kcal/day for 
women. The average daily percentages of intake for carbo-
hydrates, fat, and protein (% energy) were 34.5% ± 8.0%, 
39.6% ± 9.0%, and 19.1% ± 3.4% for men and 40.6% ± 8.1%, 
36.4% ± 7.4%, and 20.5% ± 2.4% for women, respectively 
(Table 2). The carbohydrate intake (% energy) was signifi-
cantly higher in women than in men (P = 0.010).
changes in anthropometric variables, 
cardiovascular risk factors, and antidiabetic 
drug use over 6 months
In men, the mean BMI (-0.7 ± 1.2 kg/m²), the standard devia-
tion score of BMI (-0.23 ± 0.37), HbA1c (-1.8% ± 1.4%) and 
FBG (-20 ± 42 mg/dL) were significantly decreased, and serum 
HDL-C (4.5 ± 8.8 mg/dL) levels were significantly increased 
after 6 months. However, no significant changes were observed 
in the serum LDL-C and TG levels (Table 1). In women, how-
ever, the mean BMI (-0.8 ± 1.0 kg/m²), the standard deviation 
score of BMI (-0.22 ± 0.30), HbA1c (-1.7% ± 1.6%) and 
LDL-C levels (-24 ± 27 mg/dL) were significantly decreased, 
whereas the mean serum TG and HDL-C levels were not sig-
nificantly altered after 6 months (Table 1).
Sixteen of the patients had already been prescribed antidi-
abetic drugs by other physicians before initiation of the study. 
The number of patients (n) who took sulfonylureas decreased 
and some of the remaining patients’ doses were lowered over 
the 6 months (glibenclamide: n; from 5 to 1, mean dose; from 
5 to 2.5 mg/day; glimepiride: n; from 6 to 7, mean dose; from 
2.8 to 1.5 mg/day; gliclazide: n; from 1 to 1, mean dose; 
from 80 to 20 mg/day). As for other antidiabetic drugs, the 
number of patients (n) who received nateglinide, mitiglinide, 
voglibose, and pioglitazone also decreased (nateglinide: n; 
from 1 to 0, mitiglinide: n; from 1 to 0, pioglitazone: n; from 
4 to 1, voglibose: n; from 8 to 3). The number of patients who 
took metformin slightly increased (from 5 to 7), although the 
mean dose decreased from 600 to 500 mg/day.
Table 1 changes in abdominal fat distribution and cardiovascular risk factors during the 6-month moderate low-carbohydrate diet
Men (n = 28) Women (n = 24)
Baseline After 6 months P Baseline After 6 months P
Body weight (kg) 70.7 ± 13.6 68.7 ± 12.7 0.004* 55.8 ± 7.2 54.1 ± 7.4 0.002
Body mass index (kg/m²) 25.4 ± 4.5 24.6 ± 4.1 0.003* 23.9 ± 3.4 23.2 ± 3.4 0.002
Standard deviation score of body mass index 0.49 ± 1.34 0.26 ± 1.24 0.004* 0.30 ± 0.93 0.08 ± 0.93 0.002
Systolic blood pressure (mmhg) 132 ± 23 133 ± 16 0.864 143 ± 22 134 ± 19 0.142
Diastolic blood pressure (mmhg) 81 ± 15 78 ± 9 0.813 80 ± 13 78 ± 9.6 0.460
hemoglobin A1c (%) 8.4 ± 1.5 6.5 ± 0.6 0.000 8.6 ± 2.0 7.0 ± 1.0 0.000*
Fasting blood glucose (mg/dL) 157 ± 47 136 ± 29 0.024 164 ± 50 144 ± 33 0.059
Fasting serum insulin (μiU/mL) 9.11 ± 9.11 8.18 ± 5.15 0.467* 6.63 ± 3.61 6.87 ± 3.81 0.634*
Serum triglyceride (mg/dL) 126 ± 120 110 ± 77 0.361* 112 ± 63 105 ± 59 0.468*
Serum LDL cholesterol (mg/dL) 134 ± 39 125 ± 29 0.076* 157 ± 35 133 ± 28 0.001*
Serum hDL cholesterol (mg/dL) 47 ± 13 52 ± 14 0.021* 59 ± 14 60 ± 16 0.319
VAT (cm²) 150.9 ± 57.5 129.4 ± 57.8 0.000 99.6 ± 51.7 80.0 ± 40.7 0.000*
∆VAT (cm²) -21.6 ± 26.2 -19.6 ± 19.5
%∆VAT -14.2 ± 21.6 -18.9 ± 19.0
SAT (cm²) 123.4 ± 70.7 109.9 ± 63.8 0.004 187.3 ± 70.0 168.1 ± 67.3 0.003*
∆SAT (cm²) -13.5 ± 22.8 -19.1 ± 29.9
%∆SAT -9.0 ± 23.1 -8.8 ± 17.9
TAT (cm²) 274.4 ± 106.4 239.3 ± 103.6 0.000 286.9 ± 103.5 248.1 ± 94.6 0.000
∆TAT (cm²) -35.1 ± 42.1 -38.8 ± 36.0
%∆TAT -12.8 ± 19.3 -13.4 ± 15.2
V/S ratio 1.40 ± 0.67 1.30 ± 0.58 0.069* 0.57 ± 0.30 0.49 ± 0.21 0.013*
Waist circumference (cm) 88.9 ± 10.1 86.3 ± 10.2 0.000 87.0 ± 8.8 84.6 ± 9.0 0.002
Notes:  Values  are  means  ±  SD.  Patients  receiving  lipid-lowering  drugs  (4  men  and  5  women)  were  excluded  from  the  analysis  of  lipid  profiles,  as  were  patients 
receiving  antihypertensive  drugs  (11  men  and  10  women)  from  the  analysis  of  blood  pressure;  *nonparametric  counterpart  (Wilcoxon  signed  rank  test). 
Abbreviations: VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; V/S ratio, ratio of visceral adipose tissue area to subcutaneous 
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Table 2 Daily dietary intake at 5 months after baseline
Men (n = 28) Women (n = 24)
Total energy intake (kcal) 1812 ± 375 1706 ± 323
carbohydrate (g) 153.8 ± 37.7 171.8 ± 40.5
Soluble fiber (g) 2.7 ± 1.0 3.1 ± 1.0
Insoluble fiber (g) 10.1 ± 3.7 10.6 ± 4.0
carbohydrate (% energy) 34.5 ± 8.0 40.6 ± 8.1
Fat (g) 79.4 ± 24.3 69.6 ± 21.7
Saturated fat (g) 21.7 ± 7.2 17.4 ± 6.8
Monounsaturated fat (g) 32.7 ± 11.1 27.7 ± 10.0
Polyunsaturated fat (g) 15.5 ± 5.6 15.8 ± 5.7
Fat (% energy) 39.6 ± 9.0 36.4 ± 7.4
Protein (g) 85.4 ± 19.7 86.8 ± 15.4
Protein (% energy) 19.1 ± 3.4 20.5 ± 2.4
Foods rich in carbohydrate
  rice (g) 166 ± 85 160 ± 57
  noodles (g) 41 ± 46 57 ± 61
  Bread (g) 24 ± 35 19 ± 29
  Potatoes (g) 18 ± 34 22 ± 46
  Fruit (g) 34 ± 73 64 ± 78
  confectioneries (g) 17 ± 24 19 ± 16
  Sugar (g) 7 ± 7 8 ± 7
Note: values are means ± SD.
changes in abdominal fat distribution
The parameters ∆VAT,  ∆SAT, and WC were significantly 
decreased in both men and women during the 6-month period 
(P , 0.05 for all, Table 1).
In  men,  despite  an  absolute  decrease  in VAT 
(–21.6 ± 26.2 cm²), %∆VAT (–14.2% ± 21.6%) was not 
significantly different from %∆SAT (–9.0% ± 23.1%) 
(P = 0.111). However, a significant decrease in V/S 
(P = 0.069) was not observed (Table 1). In women, along with 
an absolute decrease in VAT (–19.6 ± 19.5 cm²), %∆VAT 
(–18.9% ± 19.0%) was significantly higher than %∆SAT 
(–8.8% ± 17.9%) (P = 0.022), and V/S was also significantly 
decreased (P = 0.013).
Associations between changes  
in abdominal fat distribution  
and cardiovascular risk factors
In men, no significant correlations were observed between 
changes in abdominal adipose tissue distribution (∆VAT, 
∆SAT, ∆TAT, %∆VAT, %∆SAT, and %∆TAT) and changes 
in cardiovascular risk factors (Table 3). Meanwhile, ∆TAT, 
%∆SAT, and %∆TAT were strongly correlated with ∆FBG 
in women (r = 0.533 for ∆TAT, r = 0.417 for %∆SAT, and 
r = 0.461 for %∆TAT, Table 3). Similarly, ∆SAT, ∆TAT, 
%∆SAT, and %∆TAT were all strongly and inversely cor-
related with ∆HDL-C in women (r = -0.699 for ∆SAT, 
r = –0.567 for ∆TAT, r = –0.720 for %∆SAT, and r = –0.554 
for %∆TAT, Table 3). In addition, a significant inverse corre-
lation between ∆WC and ∆HDL-C was detected (r = –0.622), 
as was a similar correlation between either ∆SAT or ∆WC 
and ∆SBP (r = –0.543 for ∆SAT and r = –0.550 for ∆WC, 
Table 3). In contrast, only %∆VAT significantly correlated 
with ∆TG (r = 0.591, Table 3).
In multiple regression analyses that were adjusted for age, 
the following associations remained significant in women: 
between %∆VAT and ∆TG (P = 0.005), between ∆SAT 
and ∆HDL-C (P , 0.001), between %∆SAT and ∆HDL-C 
(P , 0.001), and between ∆WC and ∆HDL-C (P , 0.001). 
When five patients who had received pioglitazone, which 
influences abdominal fat distribution and serum lipid profiles, 
were excluded, the strong correlations observed in women 
were not materially altered (data not shown).
Discussion
This study is the first to show that, in outpatients with T2DM, 
a significant decrease in both VAT and SAT in men and 
women with good glycemic and BMI control, as well as 
a tapering off of sulfonylurea use and an improvement in 
serum lipid profiles, can be achieved with a moderate LCD 
(about a 38% carbohydrate diet). Significant preferential 
VAT loss was achieved in women. VAT loss was greater 
than SAT loss in men as well, but the difference did not 
reach statistical significance. At the same time, significant 
correlations of %∆SAT with ∆FBG and ∆HDL-C and sig-
nificant correlations of %∆VAT with ∆TG were observed 
only in women.
Limitations
First, the use of antidiabetic drugs (especially pioglita-
zone) that influence SAT and HDL-C may have affected 
the results.30,31 However, in the analysis that excluded 
the 4 patients who took pioglitazone, a strong correlation 
remained between the change in abdominal fat distribu-
tion and ∆HDL-C in women. Second, all the participants 
in this study were non-obese, with an average BMI (±SD) 
of 24.7 ± 4.0. Caucasians tend to be more obese and insulin 
resistant than East Asian populations.32,33 Therefore, studies 
of non-obese patients with T2DM may be more relevant to 
East Asian populations. Cross-sectional studies of apparently 
lean Japanese individuals demonstrated that a significant 
accumulation of VAT was associated with increased risk 
factors for cardiovascular disease and diabetes. These results 
were similar to what has been observed in obese patients 
with T2DM.23,34,35 Third, MRI abdomen is more accurate in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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measurement of abdominal fat compared with CT, although 
it is more expensive.36
Finally, the lack of an HCD group as a control may be 
considered a limitation, although our study aimed to evaluate 
preferential abdominal fat loss induced by LCDs.
can preferential VAT loss be achieved 
with moderate LcDs?
Most HCD intervention studies examining abdominal fat loss 
demonstrated absolute VAT and SAT loss in both sexes, as 
well as a reduction in weight.24–29,37,38 Our moderate LCD 
also significantly decreased absolute VAT and SAT and 
resulted in weight loss. These results agree with the results 
of an HCD intervention study involving non-obese Japanese 
patients with diabetes whose BMIs were similar to those 
of our patients.38 In terms of the percentage of abdominal 
fat loss, Chaston and Dixon reported that HCDs resulted 
in 8.3%–50% VAT loss and 2.6%–41% SAT loss in obese 
subjects with BMIs ranging from 26 to 40.18 Our moder-
ate LCD also resulted in a 14.2% VAT loss in men and an 
18.9% VAT loss in women, as well as a 9.0% SAT loss in 
men and an 8.8% SAT loss in women. These results suggest 
that the efficacy of moderate LCDs on absolute changes, 
and on changes in the percentage of abdominal fat loss, is 
comparable to that of HCDs.
Regarding the preferential loss of VAT or SAT, many HCD 
intervention studies have reported equivocal and inconsistent 
results. These inconsistencies may be due to the variable inter-
vention period, sex differences and the use of 2 methods (% 
loss or ratio) to assess changes in VAT and SAT. Some studies 
were conducted for approximately 3 months in women only,24 
and another was conducted for 4 weeks in men and women.19 
Several studies used V/S to assess preferential abdominal fat 
loss,19,24,27,29,37 whereas another used the percentage of loss.18 
The variety of study designs makes it difficult to compare 
results between studies. In addition, only a few of the HCD 
intervention studies used a 6-month study period or examined 
the sex difference.25,37 Collectively, there is no compelling 
evidence of preferential VAT loss resulting from intervention 
with HCDs in either women or men.18
Table 3 Spearman correlation coefficients between the change in abdominal fat distribution or WC and cardiovascular risk factors during 
the 6-month moderate low-carbohydrate diet
r
∆VAT (cm²) ∆SAT (cm²) ∆TAT (cm²) %∆VAT %∆SAT %∆TAT ∆V/S ratio ∆WC (cm)
Men (n = 28)
∆Body mass index (kg/m²) 0.533** 0.747** 0.735** 0.656** 0.707** 0.742** -0.173 0.678**
∆Standard deviation score  
of body mass index
0.544** 0.729** 0.731** 0.662** 0.697** 0.743** -0.150 0.667**
∆Systolic blood pressure (mmhg) 0.076 0.123 0.174 0.022 0.211 0.081 -0.350 0.159
∆Diastolic blood pressure (mmhg) 0.001 0.114 0.117 0.021 0.204 0.077 -0.347 0.150
∆Fasting blood glucose (mg/dL) -0.083 -0.125 -0.138 -0.094 -0.088 -0.096 0.021 0.140
∆Fasting serum insulin (μiU/mL) -0.236 0.070 -0.137 -0.075 0.123 -0.042 -0.292 0.119
∆hemoglobin A1c (%) 0.210 -0.041 0.115 0.050 -0.080 0.028 -0.006 0.055
∆Triglyceride (mg/dL) -0.110 -0.173 -0.173 -0.004 -0.128 -0.089 0.228 0.176
∆LDL–cholesterol (mg/dL) 0.058 0.174 0.078 -0.026 0.142 -0.009 -0.357 0.026
∆hDL–cholesterol (mg/dL) -0.166 0.075 -0.119 -0.243 0.085 -0.213 -0.268 -0.005
Women (n = 24)
∆Body mass index (kg/m²) 0.365 0.390 0.462* 0.596** 0.448* 0.609** -0.047 0.538**
∆Standard deviation score  
of body mass index
0.377 0.394 0.468* 0.606** 0.451* 0.615** -0.049 0.542**
∆Systolic blood pressure (mmhg) -0.037 -0.543* -0.292 -0.081 -0.455 -0.275 0.240 -0.550*
∆Diastolic blood pressure (mmhg) -0.524 -0.249 -0.444 -0.442 -0.242 -0.469 -0.213 -0.441
∆Fasting blood glucose (mg/dL) 0.282 0.381 0.533** 0.283 0.417* 0.461* -0.110 0.444*
∆Fasting serum insulin (μiU/mL) 0.293 -0.059 0.189 0.218 -0.105 0.104 0.291 0.335
∆hemoglobin A1c (%) 0.002 -0.025 0.006 0.101 0.007 0.062 0.068 0.099
∆Triglyceride (mg/dL) 0.335 -0.047 0.176 0.591** 0.032 0.290 0.381 0.141
∆LDL-cholesterol (mg/dL) -0.007 0.143 0.129 0.070 0.151 0.168 -0.030 -0.036
∆hDL-cholesterol (mg/dL) 0.042 -0.699** -0.567** -0.160 -0.720** -0.554** 0.491* -0.622**
Notes: *P , 0.05; **P , 0.01. Patients receiving lipid-lowering drugs were excluded from the analysis related to lipid profiles, as were patients receiving antihypertensive 
drugs from the analyses related to blood pressure.
Abbreviations: VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; V/S ratio, the ratio of visceral adipose tissue area to subcutaneous 
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In contrast, our 6-month moderate LCD intervention study 
demonstrates that VAT and SAT significantly decreased in 
both sexes. Furthermore, %∆VAT was greater than %∆SAT in 
men and women, but the difference did not achieve statistical 
significance in men. One possible reason for this discrepancy 
between men and women is that, compared with SAT loss, 
VAT loss may occur earlier in men.18 A study with an interme-
diate time point may have been able to detect the VAT loss, as 
well as a decrease in HbA1c levels and BMI, in men. Earlier CT 
assessment of the changes in abdominal fat distribution may 
be warranted to evaluate preferential abdominal fat loss.
The correlation between abdominal fat 
distribution and cardiovascular risk factors
LCDs induce a decrease in FBG in conjunction with a 
decrease in serum TG levels and an increase in serum HDL-C 
levels, which are characteristic of the differences between 
LCDs and HCDs.1–5 This study demonstrates the correla-
tions of changes in abdominal fat distribution with ∆FBG, 
∆HDL-C, and ∆TG in women. Our results suggest that the 
major benefit of moderate LCDs is abdominal fat loss in 
patients with T2DM who have higher serum TG levels and/
or lower serum HDL-C levels.
Although numerous HCD intervention studies have been 
conducted, relatively little is known about the correlations 
between %∆VAT or %∆SAT and changes in cardiovascular 
risk factors in patients on HCDs. One researcher has described 
correlations between ∆VAT and ∆TG, as well as ∆V/S and 
∆FBG.27 Others have described correlations between ∆VAT 
and ∆FBG, ∆insulin and either ∆total cholesterol or ∆LDL-C 
and ∆SAT and either ∆total cholesterol or ∆LDL-C.28 The 
inconsistent results from the serum lipid profiles seem to be 
due to the high-carbohydrate conditions.
We focused on which adipose tissues contribute more to 
changes in cardiovascular risk factors. Concerning the above 
3 cardiovascular risk factors, %∆SAT was correlated with 
two (∆FBG and ∆HDL-C) of the factors, while %∆VAT 
was correlated with one (∆TG). Taking into consideration 
the recent reviews that describe no compelling evidence of 
weight loss due to intervention with HCDs and/or exercise 
that targets preferential VAT loss,18 our study may provide 
evidence that SAT increases cardiovascular risk to the same 
extent as VAT in women.
Conclusion
A significant decrease in absolute VAT and SAT in men and 
women with good glycemic and BMI control, as well as a 
tapering off of sulfonylurea use and the improvement of the 
serum lipids profiles, can be achieved with the a moderate LCD. 
Significant preferential VAT loss was achieved in women, and 
VAT loss was greater than SAT loss in both men and women, 
although the difference was not statistically significant in men. 
Concomitantly, significant correlations of %∆SAT with ∆HDL, 
as well as ∆FBG and %∆VAT with ∆TG were observed in 
women. We suggest that the moderate LCD may be effective 
for preferential VAT loss in patients with T2DM who have 
lower serum HDL-C and/or higher serum TG levels, and that 
both VAT and SAT may influence CRFs in female patients 
with T2DM who are following a moderate LCD.
However, we did not find a significant association 
between abdominal fat loss and changes in cardiovascular 
risk factors in men. Further detailed studies with intermediate 
assessments are required to clarify the relationship between 
preferential abdominal fat loss and changes in cardiovascular 
risk factors.
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